Latest Bare-metal stent Stories
NATICK, Mass., March 7, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its OMEGA(TM) Platinum Chromium Bare-Metal Coronary Stent System, the Company's third-generation coronary stenting technology.
DURHAM, N.C., Feb. 17, 2011 /PRNewswire/ -- Micell Technologies,(TM) Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial.
NATICK, Mass., Jan. 24, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY(TM) Coronary Stent.
HONG KONG, Dec.
DURHAM, N.C., Nov. 29, 2010 /PRNewswire/ -- Micell Technologies,(TM) Inc.
TORONTO, Nov. 3, 2010 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, novel drug-coated balloon technology is being adopted in niche applications throughout Europe.
NATICK, Mass., Sept. 25 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from the HORIZONS-AMI trial.
TCT- WASHINGTON, September 23, 2010 /PRNewswire/ -- InspireMD, developers of the novel MGuard(TM) coronary MicroNet stent system, will introduce MGuard Prime at its booth #2052 at the TCT Conference in Washington DC, September 23-25, 2010.
NATICK, Mass., Sept.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.